Clinical Trials · NCT02275338

Study to Assess Efficacy and Safety of Lanreotide Autogel 120 MG in Treatment of Clinical Symptoms Associated With Inoperable Malignant Intestinal Obstruction

Name: Study to Assess Efficacy and Safety of Lanreotide Autogel 120 MG in Treatment of Clinical Symptoms Associated With Inoperable Malignant Intestinal Obstruction
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

CompletedPhase 2Lanreotide

Phase: Phase 2
Recruitment status: Completed
Sponsor: Ipsen
Enrollment: 52
Start date: Nov 2014
Locations: 17 sites, Belgium
Primary endpoint: Percentage of Responders Before or at Day 7

View Lanreotide compound reference